Strata Critical Medical (SRTA) Capital Expenditures (2021 - 2026)

Strata Critical Medical has disclosed Capital Expenditures across 6 years of filings, most recently posting $5.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 1427.73% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.0 million (up 132.72% YoY), while the FY2025 annual figure was $128000.0, down 65.87% from the prior year.
• Capital Expenditures rose to $5.2 million in Q1 2026, from -$7.6 million in the prior quarter.
• Over the last five years, Capital Expenditures for SRTA reached as high as $7.6 million in Q3 2024 and fell as low as -$25.9 million in Q4 2024.
• The 5-year median for Capital Expenditures is $816000.0 (2024), against an average of -$641307.7.
• Annual changes were most pronounced in 2024 — Capital Expenditures tumbled 1142.73% — and 2026, when it soared 1427.73%.
• A 5-year view of Capital Expenditures shows it stood at $626000.0 in 2022, then slumped by 433.07% to -$2.1 million in 2023, then plunged by 1142.73% to -$25.9 million in 2024, then soared by 70.6% to -$7.6 million in 2025, then surged by 167.97% to $5.2 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $5.2 million, -$7.6 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.